Could Earlier Access to a Promising Drug Change the Outlook for Pancreatic Cancer?

For patients with metastatic pancreatic cancer, treatment options beyond first-line chemotherapy remain extremely limited. Outcomes are often measured in months, not years. 

A recent decision by the U.S. Food and Drug Administration to permit expanded access to the investigational drug daraxonrasib is drawing attention across the oncology community. The move allows certain patients to receive the therapy ahead of formal approval, offering a potential new option in a disease with few effective treatments. 

The @US_FDA has issued a "safe to proceed" letter allowing the initiation of an expanded access treatment protocol (EAP) for daraxonrasib, an experimental drug targeting pancreatic cancer. Per EAP guidelines, requests must be submitted to the sponsor by U.S.-licensed physicians… pic.twitter.com/W6JTjDFWZy

— U.S. FDA (@US_FDA) May 1, 2026

For Ignacio Garrido-Laguna, MD, PhD, chair of the Early Therapeutics Development Department at Moffitt Cancer Center, the significance is immediate. 

“This is incredibly meaningful,” he said. “This will allow patients who have no good treatment options to access a drug that is likely to be approved in the coming months, without having to wait.” 

A Signal of Urgency 

Pancreatic cancer remains one of the most challenging cancers to treat. After first-line therapy, the effectiveness of chemotherapy drops significantly, with median overall survival around six months. 

Against that backdrop, the FDA’s rapid action stands out. 

“The speed at which this has moved reflects both the urgency of the disease and the collaboration between the FDA and the sponsor to bring therapies to patients as quickly as possible,” Garrido-Laguna said.  

Targeting a Common Driver 

What makes daraxonrasib especially notable is its target. 

The drug is a molecular glue that induces interaction between cyclophilin A, a protein that drives cancer progression, and RAS proteins which act as an on/off switch in cell signaling.  This regulates cell signaling, thereby blocking oncogenic RAS signaling, which is activated in about 90% of pancreatic cancers. These RAS mutations are considered a foundational driver of the disease and often occur years before tumors are detectable. 

“For decades, KRAS was considered undruggable,” Garrido-Laguna said. “Now we have a therapy that targets a genetic vulnerability present in the vast majority of pancreatic cancer patients.” 

For decades, KRAS was considered undruggable. Now we have a therapy that targets a genetic vulnerability present in the vast majority of pancreatic cancer patients.

Ignacio Garrido-Laguna, MD, PhD

Unlike existing second-line options, which rely largely on chemotherapy, this approach represents a shift toward precision medicine in pancreatic cancer, an area where targeted therapies have historically benefited only a small subset of patients. 

A Meaningful Option for Patients 

For patients who have exhausted standard treatments, the impact could be significant. 

“It gives patients a chance to continue to fight the disease” Garrido-Laguna said.  

Early data suggests the drug may extend survival compared to chemotherapy, with median survival reaching more than a year according to recent data from the RASolute-302 study. While those results are still being evaluated, they point to a potential shift in expectations for a disease where survival gains have been minimal. 

“We are starting to move from outcomes measured in months toward survival that extends well beyond a year,” he said. 

An experimental pancreatic cancer drug that’s been shown to double survival in patients with advanced stages of the disease is poised to revolutionize the way the cancer is treated, oncologists say. https://t.co/HAGhnYB5eo

— NBC News (@NBCNews) May 7, 2026

Balancing Access and Uncertainty 

Expanded access programs come with trade-offs. While they provide patients with earlier access to promising therapies, they also introduce logistical and clinical hurdles. 

Institutions must be ready to manage increased demand from heavily pretreated patients. Clinicians will be responsible for determining which patients meet eligibility criteria for expanded access program and will need to ensure equitable access.  

“There will be operational challenges as more patients seek access to this drug,” Garrido-Laguna said, noting that health systems will need to adapt quickly. 

There are also scientific considerations. Because the drug is still investigational, questions remain about long-term outcomes, strategies to treatment resistance and how to best manage side effects, such as skin rash that occurs in about 90% of patients. 

What Comes Next? 

Daraxonrasib, was awarded a National Priority Voucher by the FDA in October 2025 and is expected to move through the FDA review process on an expeditious timeline, with a decision anticipated in the coming months. 

Once approved, it will become the new backbone of therapy in pancreatic cancer that could also be used in combination with other treatments, marking a turning point in how the disease is treated. Daraxonrasib is also undergoing evaluation in patients with resected pancreatic cancer following completion of adjuvant treatment as well as in combination with chemotherapy or as a single agent in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma. 

More broadly, the decision to grant expanded access reflects a shift in how regulators, researchers and clinicians are approaching life-threatening diseases with limited options. 

“It brings hope,” Garrido-Laguna said. “For patients who previously had no path forward, this offers a chance to keep fighting.”